Top Markets
Coin of the day
Mendus AB (publ) Mendus AB (publ)

Mendus AB (publ)

IMMU
Rank in Stocks #25836
Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB... Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.
Share Price
$0.74834668
Market Cap
$45.86M
Change (1 day)
-0.15%
Change (1 year)
-6.28%
Country
SE
Trade Mendus AB (publ) (IMMU)

Category

P/S ratio for Mendus AB (publ) (IMMU)
P/S ratio as of 2026 TTM: 0
According to Mendus AB (publ) latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Mendus AB (publ) from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.17 -
US
10.13 -
NL
2.95 -
AU
- -
CH
11.28 -
US